María de Jesús Ibarra-Sánchez

Dr. María de Jesús Ibarra-Sánchez

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JEJosé Esparza-López
José Esparza-López
JAJuan Francisco Alvarado-Muñoz
Juan Francisco Alvarado-Muñoz
EEElizabeth Escobar-Arriaga
Elizabeth Escobar-Arriaga
AUAlfredo Ulloa-Aguirre
Alfredo Ulloa-Aguirre
MIMaría de Jesús Ibarra-Sánchez
María de Jesús Ibarra-Sánchez
Breast cancer currently is the most frequently diagnosed neoplasm and the leading cause of death from cancer in women worldwide, which is mainly due to metastatic disease. Increasing our understanding of the molecular mechanisms leading to metastasis might thus improve the pharmacological management of the disease. Epithelial-mesenchymal transition (EMT) is a key factor that plays a major role in tumor metastasis. Some pro-inflammatory cytokines, like IL-6, have been shown to stimulate phenotypes consistent with EMT in transformed epithelial cells as well as in carcinoma cell lines. Since the EMT is one of the crucial steps for metastasis, we studied the effects of metformin (MTF) on EMT. Cytotoxic effect of MTF was evaluated in eight primary breast cancer cell cultures by crystal violet assay. EMT markers and downstream signaling molecules were measured by Western blot. The effect of MTF on cell proliferation and cell migration were analyzed by MTT and Boyden chamber assays respectively. We observed that the response of cultured breast cancer primary cells to MTF varied; mesenchymal cells were resistant to 10 mM MTF and expressed Vimentin and SNAIL, which are associated with a mesenchymal phenotype, whereas epithelial cells were sensitive to this MTF dose, and expressed E-cadherin but not mesenchymal markers. Further, exposure of mesenchymal cells to MTF down-regulated both Vimentin and SNAIL as well as cell proliferation, but not cell migration. In an in vitro IL-6-induced EMT assay, primary breast cancer cells showing an epithelial phenotype underwent EMT upon exposure to IL-6, with concomitant activation of STAT3 and NF-κB; addition of MTF to IL-6-induced EMT reversed the expression of the mesenchymal markers Vimentin and SNAIL, decreased pSTAT3 Y705 and pNF-κB S536 and increased E-cadherin. In addition, downregulation of STAT3·activation was dependent on AMPK, but not NF-κB phosphorylation. Further, MTF inhibited cell proliferation and migration stimulated by IL-6. These results suggest that MTF inhibits IL-6-induced EMT, cell proliferation, and migration of primary breast cancer cells by preventing the activation of STAT3 and NF-κB. STAT3 inactivation occurs through AMPK, but not NF-κB.

15 December 2021 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JEJosé Esparza‑López
José Esparza‑López
OLOssian Longoria
Ossian Longoria
ECEliseo Neftali De La Cruz‑Escobar
Eliseo Neftali De La Cruz‑Escobar
JGJulio Cesar Garibay‑Díaz
Julio Cesar Garibay‑Díaz
ELEucario León‑Rodríguez
Eucario León‑Rodríguez
MIMaría de Jesús Ibarra-Sánchez
María de Jesús Ibarra-Sánchez
Paclitaxel has been used widely to treat breast cancer and other types of cancer. However, resistance is a major cause of failure for treatment and results in cancer progression. The present study investigated the association between paclitaxel resistance and the mesenchymal phenotype, using a model of primary breast cancer cells and employing four different cultures, two with an epithelial phenotype (MBCDF and MBCD17) and two with a mesenchymal phenotype (MBCDF-D5 and MBCD3). Epithelial-mesenchymal markers were evaluated by western blotting; MBCDF and MBCD17 cells expressed E-cadherin, SNAIL, Slug, and Twist, low levels of N-cadherin, but not vimentin. MBCDF-D5 and MBCD3 cells expressed N-cadherin, vimentin, and higher levels of SNAIL, and low levels of E-cadherin, Slug, and Twist. Cell viability was evaluated using a crystal violet assay after paclitaxel treatment; primary breast cancer cells with mesenchymal phenotype were resistant to paclitaxel compared with the epithelial primary breast cancer cells. Furthermore, using western blotting, it was revealed that mesenchymal cells had elevated levels of nuclear factor-kappa Beta (NF-kappa B) p65 and I kappa B kinase (IKK). Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappa B, activation of NF-kappa B in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation. Finally, employing western blotting and crystal violet assays, the effects of the proteasome inhibitor ALLN were assessed. ALLN inhibited paclitaxel-induced NF-kappa B activation and restored the sensitivity to paclitaxel. Together, these data suggest that targeting the NF-kappa B/IKK axis might be a promising strategy to overcome paclitaxel resistance.

Verified
Journal Article
Open access
PDF file
Gabriela Morales-GuadarramaGabriela Morales-Guadarrama
Gabriela Morales-Guadarrama
EPEdgar Armando Méndez Pérez
Edgar Armando Méndez Pérez
JGJanice Garcia-Quiroz
Janice Garcia-Quiroz
EAEuclides Avila
Euclides Avila
MIMaría de Jesús Ibarra-Sánchez
María de Jesús Ibarra-Sánchez
Lorenza DiazLorenza Diaz
Lorenza Diaz
Vasculogenic mimicry (VM), a process in which aggressive cancer cells form tube-like structures, plays a crucial role in providing nutrients and escape routes. Highly plastic tumor cells, such as those with the triple-negative breast cancer (TNBC) phenotype, can develop VM. However, little is known about the interplay between the cellular components of the tumor microenvironment and TNBC cells’ VM capacity. In this study, we analyzed the ability of endothelial and stromal cells to induce VM when interacting with TNBC cells and analyzed the involvement of the FGFR/PI3K/Akt pathway in this process. VM was corroborated using fluorescently labeled TNBC cells. Only endothelial cells triggered VM formation, suggesting a predominant role of paracrine/juxtacrine factors from an endothelial origin in VM development. Via immunocytochemistry, qPCR, and secretome analyses, we determined an increased expression of proangiogenic factors as well as stemness markers in VM-forming cancer cells. Similarly, endothelial cells primed by TNBC cells showed an upregulation of proangiogenic molecules, including FGF, VEGFA, and several inflammatory cytokines. Endothelium-dependent TNBC-VM formation was prevented by AZD4547 or LY294002, strongly suggesting the involvement of the FGFR/PI3K/Akt axis in this process. Given that VM is associated with poor clinical prognosis, targeting FGFR/PI3K/Akt pharmacologically may hold promise for treating and preventing VM in TNBC tumors.

20 September 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JEJosé Esparza-López
José Esparza-López
PRPier A. Ramos-Elías
Pier A. Ramos-Elías
ACAndrea Castro-Sánchez
Andrea Castro-Sánchez
LRLeticia Rocha-Zavaleta
Leticia Rocha-Zavaleta
EEElizabeth Escobar-Arriaga
Elizabeth Escobar-Arriaga
MIMaría de Jesús Ibarra-Sánchez
María de Jesús Ibarra-Sánchez
It has become evident that intra-tumor heterogeneity of breast cancer impact on several biological processes such as proliferation, migration, cell death and also might contribute to chemotherapy resistance. The expression of Receptor Tyrosine Kinases (RTKs) has not been analyzed in the context of intra-tumor heterogeneity in a primary breast cancer cell culture. Several subpopulations were isolated from the MBCDF (M serial-breast cancer ductal F line) primary breast cancer cells and were successfully maintained in culture and divided in two groups according to their morphology and RTKs expression pattern, and correlated with biological processes like proliferation, migration, anchorage-independent cell growth, and resistance to cytotoxic chemotherapy drugs and tyrosine kinase inhibitors (TKIs). Subpopulations were isolated from MBCDF primary breast cancer cell culture by limiting dilution. RTKs and hormone receptors were examined by Western blot. Proliferation was measure by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT assay). Cell viability was evaluated by Crystal Violet. Migration was assessed using Boyden chambers. Anchorage-independent cell growth was evaluated by colony formation in soft agar. Several subpopulations were isolated from the MBCDF breast cancer cells that were divided into two groups according to their morphology. Analysis of RTKs expression pattern showed that HER1, HER3, c-Met and VEGFR2 were expressed exclusively in cells from group 1, but not in cells from group 2. PDGFR was expressed only in cells from group 2, but not in cells from group 1. HER2, HER4, c-Kit, IGF1-R were expressed in all subpopulations. Biological processes correlated with the RTKs expression pattern. Group 2 subpopulations present the highest rate of cell proliferation, migration and anchorage-independent cell growth. Analysis of susceptibility to chemotherapy drugs and TKIs showed that only Paclitaxel and Imatinib behaved differently between groups. Group 1-cells were resistant to both Paclitaxel and Imatinib. We demonstrated that subpopulations from MBCDF primary cell culture could be divided into two groups according to their morphology and a RTKs excluding-expression pattern. The differences observed in RTKs expression correlate with the biological characteristics and chemoresistance of each group. These results suggest that intra-tumor heterogeneity contributes to generate groups of subpopulations with a more aggressive phenotype within the tumor.

1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AAAlain Aguilar-Valdés
Alain Aguilar-Valdés
LNLilia G. Noriega
Lilia G. Noriega
ATArmando R. Tovar
Armando R. Tovar
MIMaría de Jesús Ibarra-Sánchez
María de Jesús Ibarra-Sánchez
VSVíctor A. Sosa-Hernández
Víctor A. Sosa-Hernández
JMJuan Martínez-Aguilar
Juan Martínez-Aguilar

3 March 2021 in Processes
Verified
Journal Article
Open access
PDF file
GLGalia Lara-Sotelo
Galia Lara-Sotelo
Lorenza DiazLorenza Diaz
Lorenza Diaz
RGRocío García-Becerra
Rocío García-Becerra
EAEuclides Avila
Euclides Avila
HPHeriberto Prado-Garcia
Heriberto Prado-Garcia
JGJanice Garcia-Quiroz
Janice Garcia-Quiroz
Breast cancer is the most common neoplasm and the leading cause of cancer death in women worldwide. Although 5-fluorouracil is a conventional chemotherapeutic agent for breast cancer treatment, its use may result in severe side effects. Thus, there is widespread interest in lowering 5-fluorouracil drawbacks, without affecting its therapeutic efficacy by the concomitant use with natural products. Herein, we aimed at evaluating whether α-mangostin, a natural antineoplastic compound, could increase the anticancer effect of 5-fluorouracil in different breast cancer cell lines, allowing for dose reduction. Cell proliferation was evaluated by sulforhodamine-B assays, inhibitory concentrations and potency were calculated by dose-response curves, followed by analysis of their pharmacological interaction by the combination-index method and dose-reduction index. Cell cycle distribution was evaluated by flow cytometry. Each compound inhibited cell proliferation in a dose-dependent manner, the triple negative breast cancer cells being the most sensitive. When 5-fluorouracil and α-mangostin were used concomitantly, synergistic antiproliferative effect was observed. The calculated dose-reduction index suggested that this combination exhibits therapeutic potential for reducing 5-fluorouracil dosage in breast cancer. Mechanistically, the cotreatment induced cell death in a greater extent than each drug alone. Therefore, α-mangostin could be used as a potent co-adjuvant for 5-fluorouracil in breast cancer.